AAA. Arakawa

A. Arakawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. Arakawa has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Y. Miyachi

    Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Kawahara‐cho, Shogoin, Sakyo Kyoto 606‐8507, Japan

    2 shared publications
  • A. Kitoh

    Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Kawahara‐cho, Shogoin, Sakyo Kyoto 606‐8507, Japan

    1 shared publication
  • H. Fujii

    Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo Kyoto 606-8507, Japan

    1 shared publication
  • M. Kato

    Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Kawahara‐cho, Shogoin, Sakyo Kyoto 606‐8507, Japan

    1 shared publication
  • M. Miyara

    Laboratoire d’immunochimie

    1 shared publication
  • M. Tanioka

    Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Kawahara‐cho, Shogoin, Sakyo Kyoto 606‐8507, Japan

    1 shared publication

Latest Publications

  • Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma

    by H. Fujii, A. Arakawa, A. Kitoh, M. Miyara, M. Kato, S. Kore-Eda, S. Sakaguchi, Y. Miyachi, M. Tanioka, M. Ono

    Background ‘FOXP3+ regulatory T cells’ (Tregs) are reported to be increased in tumour‐bearing hosts including patients with melanoma, leading to tumour immune suppression. However, this idea is challenged by recent evidence that the ‘FOXP3+ Treg’ fraction in fact contains activated ‘nonregulatory’ T cells. Also, FOXP3+ T cells are reported to have functionally and kinetically distinct subsets. Objectives To investigate whether either or both of regulatory and ‘nonregulatory’ FOXP3+ T cells are perturbed in patients with melanoma. Methods FOXP3+ T cells were classified into three subsets, namely CD45RO+FOXP3low nonregulatory T cells, CD45RO+FOXP3high effector Tregs, and CD45RO−FOXP3low naïve Tregs, according to their expression levels of FOXP3 and CD45RO. The percentage and cytokine production of these FOXP3+ T‐cell subsets were assessed by flow cytometry. Results Both regulatory and nonregulatory T cells were increased in patients with melanoma. Moreover, we found three unexpected perturbations in FOXP3+ T‐cell subsets: (i) patients with melanoma showed higher frequencies of FOXP3low nonregulatory T cells, which decreased and normalized after tumour removal; (ii) FOXP3low naïve Tregs containing higher frequencies of interferon‐γ+ cells increased with tumour progression; and (iii) CD45RO+FOXP3high effector Tregs were pronouncedly infiltrated around tumour tissues. Conclusions These findings demonstrate that patients with melanoma have distinct and differential perturbation of both regulatory and nonregulatory FOXP3+ T cells. The degree of perturbation is associated with tumour burden and progression, suggesting that the perturbation reflects fundamental pathophysiological processes in patients with melanoma. The presented analysis provides a practical approach to investigate the immunological environment of cancer patients.


  • Genotyping ofTrichophyton tonsuransisolate from a Japanese boy reveals infection in the USA

    by A. Arakawa, N. Kanazawa, S. Tanaka, M. Yonezawa, Y. Miyachi, T. Mochizuki